Skip to main content
. 2016 Jun 3;10(5):300–308. doi: 10.1097/ADM.0000000000000223

TABLE 1.

Naloxone Formulations and Features

Injectable (and Nasal) Generic Intranasal Branded Injectable Generic Auto-injector Branded
graphic file with name adm-10-300-g002.jpg
FDA approval X (for IV, IM, SC) X X X
Layperson experience X X X
Fragile; requires assembly X X
Can titrate dose X X
Strength 1 mg/mL 4 mg/0.1 mL 0.4 mg/mL or 4 mg/10 mL 0.4 mg/0.4 mL
Cost per kit $$ $$ $ $$$
Rx and quantity #2, 2 mL Luer-Jet Luer-Lock needleless syringe plus #2 mucosal atomizer devices (MAD-300) #1 two-pack of two 4-mg/0.1 mL intranasal devices #2 single-use 1-mL vials or #1 10-mL multidose fliptop vial PLUS #2 3 mL syringe with 23 to 25 gauge 1–1.5 inch IM needles #1 two-pack of two 0.4 mg/0.4 mL prefilled auto-injector devices
Sig. (for suspected opioid overdose) Spray 1 mL (1/2 of syringe) into each nostril. Repeat after 2 to 3 minutes if no or minimal response Spray 0.1 mL into one nostril. Repeat with second device into other nostril after 2 to 3 minutes if no or minimal response Inject 1 mL in shoulder or thigh. Repeat after 2 to 3 minutes if no or minimal response Inject into outer thigh as directed by English voice-prompt system. Place black side firmly on outer thigh and depress and hold for 5 seconds. Repeat with second device in 2 to 3 minutes if no or minimal response

Some portions developed with funding from NIDA R01 DA034634.